153 related articles for article (PubMed ID: 19337629)
1. The role of serum chromogranin A in diarrhoea predominant irritable bowel syndrome.
Sidhu R; McAlindon ME; Leeds JS; Skilling J; Sanders DS
J Gastrointestin Liver Dis; 2009 Mar; 18(1):23-6. PubMed ID: 19337629
[TBL] [Abstract][Full Text] [Related]
2. Chromogranin A as a possible tool in the diagnosis of irritable bowel syndrome.
El-Salhy M; Lomholt-Beck B; Hausken T
Scand J Gastroenterol; 2010 Dec; 45(12):1435-9. PubMed ID: 20602602
[TBL] [Abstract][Full Text] [Related]
3. [Serum serotonin concentration and urine 5-hydroxyindole acetic acid excretion in patients with irritable bowel syndrome].
Moskwa A; Chojnacki J; Wiśiewska-Jarosińska M; Stec-Michalska K; Szadkowski K; Smigielski J; Chojnacki C
Pol Merkur Lekarski; 2007 May; 22(131):366-8. PubMed ID: 17679369
[TBL] [Abstract][Full Text] [Related]
4. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
[TBL] [Abstract][Full Text] [Related]
5. Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study.
Zissimopoulos A; Vradelis S; Konialis M; Chadolias D; Bampali A; Constantinidis T; Efremidou E; Kouklakis G
Scand J Gastroenterol; 2014 Aug; 49(8):942-9. PubMed ID: 24897131
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome.
Chang FY; Lu CL; Chen CY; Luo JC
J Gastroenterol Hepatol; 2007 Dec; 22(12):2266-72. PubMed ID: 17559369
[TBL] [Abstract][Full Text] [Related]
7. Interactions between symptoms and motor and visceral sensory responses of irritable bowel syndrome patients to spasmolytics (antispasmodics).
Khalif IL; Quigley EM; Makarchuk PA; Golovenko OV; Podmarenkova LF; Dzhanayev YA
J Gastrointestin Liver Dis; 2009 Mar; 18(1):17-22. PubMed ID: 19337628
[TBL] [Abstract][Full Text] [Related]
8. Validation of serum versus plasma measurements of chromogranin a levels in patients with carcinoid tumors: lack of correlation between absolute chromogranin a levels and symptom frequency.
Woltering EA; Hilton RS; Zolfoghary CM; Thomson J; Zietz S; Go VL; Vinik AI; Vinik E; O'Dorisio TM; Mamikunian G
Pancreas; 2006 Oct; 33(3):250-4. PubMed ID: 17003646
[TBL] [Abstract][Full Text] [Related]
9. Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes.
Bleser S
Curr Med Res Opin; 2011 Mar; 27(3):503-12. PubMed ID: 21208139
[TBL] [Abstract][Full Text] [Related]
10. Reduced chromogranin A cell density in the ileum of patients with irritable bowel syndrome.
El-Salhy M; Wendelbo IH; Gundersen D
Mol Med Rep; 2013 Apr; 7(4):1241-4. PubMed ID: 23426642
[TBL] [Abstract][Full Text] [Related]
11. Subtyping the irritable bowel syndrome by predominant bowel habit: Rome II versus Rome III.
Ersryd A; Posserud I; Abrahamsson H; Simrén M
Aliment Pharmacol Ther; 2007 Sep; 26(6):953-61. PubMed ID: 17767480
[TBL] [Abstract][Full Text] [Related]
12. Assessment of high-sensitivity CRP as a marker of micro-inflammation in irritable bowel syndrome.
Hod K; Dickman R; Sperber A; Melamed S; Dekel R; Ron Y; Halpern Z; Berliner S; Maharshak N
Neurogastroenterol Motil; 2011 Dec; 23(12):1105-10. PubMed ID: 21951717
[TBL] [Abstract][Full Text] [Related]
13. The effect of trimebutine on the psychosocial adjustment to illness in the irritable bowel syndrome.
Dumitraşcu DL; Stănculete M
Rom J Intern Med; 2006; 44(3):273-80. PubMed ID: 18386606
[TBL] [Abstract][Full Text] [Related]
14. Treatment of diarrhea-predominant irritable bowel syndrome with traditional Chinese herbal medicine: a randomized placebo-controlled trial.
Leung WK; Wu JC; Liang SM; Chan LS; Chan FK; Xie H; Fung SS; Hui AJ; Wong VW; Che CT; Sung JJ
Am J Gastroenterol; 2006 Jul; 101(7):1574-80. PubMed ID: 16863563
[TBL] [Abstract][Full Text] [Related]
15. Prevalence, bowel habit subtypes and medical care-seeking behaviour of patients with irritable bowel syndrome in Northern Greece.
Katsinelos P; Lazaraki G; Kountouras J; Paroutoglou G; Oikonomidou I; Mimidis K; Koutras C; Gelas G; Tziomalos K; Zavos C; Pilpilidis I; Chatzimavroudis G
Eur J Gastroenterol Hepatol; 2009 Feb; 21(2):183-9. PubMed ID: 19212207
[TBL] [Abstract][Full Text] [Related]
16. Lactose intolerance in patients with irritable bowel syndrome from northern India: a case-control study.
Gupta D; Ghoshal UC; Misra A; Misra A; Choudhuri G; Singh K
J Gastroenterol Hepatol; 2007 Dec; 22(12):2261-5. PubMed ID: 17559357
[TBL] [Abstract][Full Text] [Related]
17. Chromogranin-A and N-terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor.
Korse CM; Taal BG; de Groot CA; Bakker RH; Bonfrer JM
J Clin Oncol; 2009 Sep; 27(26):4293-9. PubMed ID: 19667278
[TBL] [Abstract][Full Text] [Related]
18. Impact of upper digestive symptoms in patients with irritable bowel syndrome.
Balboa A; Mearin F; Badía X; Benavent J; Caballero AM; Domínguez-Muñoz JE; Garrigues V; Piqué JM; Roset M; Cucala M; Figueras M;
Eur J Gastroenterol Hepatol; 2006 Dec; 18(12):1271-7. PubMed ID: 17099375
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin analog inhibits afferent response to rectal distention in diarrhea-predominant irritable bowel patients.
Hasler WL; Soudah HC; Owyang C
J Pharmacol Exp Ther; 1994 Mar; 268(3):1206-11. PubMed ID: 8138933
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome.
Vahedi H; Merat S; Momtahen S; Kazzazi AS; Ghaffari N; Olfati G; Malekzadeh R
Aliment Pharmacol Ther; 2008 Apr; 27(8):678-84. PubMed ID: 18248658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
